(2)
Vancouver, British Columbia (Newsfile Corp. - April 29, 2021) - iCo Therapeutics ( iCo or the Company ) (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ( IFRS ).
William Jarosz, CEO of iCo Therapeutics Inc., noted We were very pleased by the progress of our Oral Amp B program during the year with our compound being safe and well tolerated in Phase 1b clinical trials and potential as a therapeutic agent for novel Coronavirus. We are also excited for the new strategic directions that are open for us in this new year with Satellos, and the associated concurrent financing, previously announced.
Australia
United-states
Canada
United-kingdom
Vancouver
British-columbia
Australian
British
Canadian
William-jarosz
Susan-koppy
Venture-exchange-the